Summary of R&D Pipeline and Agreement Status

Product Candidates

Indication

R&D Status

Agreement Status

Territory Available

TriptoSar

Cancer

Phase I Human trials - US, France

PFM

China, Taiwan & Hong Kong

WilGraf

Organ transplantation, autoimmune & skin

Primates

Option agreement w/ Fujisawa

Worldwide

WilVent

Lung diseases -Pulmonary fibrosis -Obliterative airway disease & SARS

Small animal

Open

Worldwide

NeurTriptin

Neuroprotection  
- Alzheimer’s  

- Parkinson’s  

- ALS diseases

In vitro

Open

Worldwide

PG27

Rheumatoid arthritis

Small animals

PhytoHealth - Taiwan

Rest of world excluding China & Taiwan

Injectable Astragalus Polysaccharide (PG2)

Adjunctive treatment to cancer therapy
Restores WBCs

Product launch

TJHL – China

Rest of world excluding China & Taiwan

XueBao  
(PG2)

Adjunctive treatment to cancer therapy  
Restores WBCs

Phase II Human trials

PhytoHealth - Taiwan

Rest of world excluding China & Taiwan

AstraStim

Adjunctive treatment to cancer therapy  
Restores WBCs, RBCs and Platelets

Small animals

Open

Worldwide

PG36

CMV Infection

Small animals

Open

Worldwide

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[ Pipeline ] Research ] Development ] New Areas ] PG490 Supply ] PG2 ] PG2-2000 ] B50 ] PG36 ] Collaborations ] Discovery ] Publications ]

Home ] Management ] R&D ] IP ] Contact ] Site Map ]